SKP

SK pharmteco is a global contract development and manufacturing organization (CDMO) that provides end-to-end services for the pharmaceutical and biotech industries. As a subsidiary of the South Korean conglomerate SK Inc., the company specializes in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy (CGT) products. SK pharmteco operates a robust manufacturing network across North America, Europe, and Asia, offering expertise in complex chemistry, continuous manufacturing, and high-potency API handling. Through strategic acquisitions of entities like Yposkesi and the Center for Breakthrough Medicines (CBM), the company has established a significant presence in the rapidly growing advanced biotherapeutics market.